Loss of ERα induces amoeboid-like migration of breast cancer cells by downregulating vinculin.

Nature communications (2017-03-08)
Yuan Gao, Zhaowei Wang, Qiang Hao, Weina Li, Yujin Xu, Juliang Zhang, Wangqian Zhang, Shuning Wang, Shuo Liu, Meng Li, Xiaochang Xue, Wei Zhang, Cun Zhang, Yingqi Zhang
RESUMEN

Oestrogen receptor alpha (ERα) is a well-known target of endocrine therapy for ERα-positive breast cancer. ERα-negative cells, which are enriched during endocrine therapy, are associated with metastatic relapse. Here we determine that loss of ERα in the invasive front and in lymph node metastasis in human breast cancer is significantly correlated with lymphatic metastasis. Using in vivo and in vitro experiments, we demonstrate that ERα inhibits breast cancer metastasis. Furthermore, we find that ERα is a novel regulator of vinculin expression in breast cancer. Notably, ERα suppresses the amoeboid-like movement of breast cancer cells by upregulating vinculin in 3D matrix, which in turn promotes cell-cell and cell-matrix adhesion and inhibits the formation of amoeboid-like protrusions. A positive association between ERα and vinculin expression is found in human breast cancer tissues. The results show that ERα inhibits breast cancer metastasis and suggest that ERα suppresses cell amoeboid-like movement by upregulating vinculin.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
E-Cadherin human, recombinant, expressed in E. coli, 0.5 mg protein/mL

Redes sociales

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Investigación. Desarrollo. Producción.

Somos un proveedor líder para la industria de Ciencias de la Vida con soluciones y servicios para investigación, desarrollo y producción biotecnológicos, y para desarrollo y producción de tratamientos farmacéuticos

© 2021 Merck KGaA, Darmstadt, Alemania y/o sus filiales. Todos los derechos reservados.

Queda estrictamente prohibida la reproducción sin permiso de cualquiera de los materiales de la página web.